858 Extrawell Pharmaceutical Holdings Limited HKEX · Hong Kong

Extrawell Pharmaceutical Holdings (858) news

Extrawell Pharmaceutical Holdings Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 858, recorded under Hong Kong. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Extrawell Pharmaceutical Holdings news

We have not published a story on Extrawell Pharmaceutical Holdings yet. When there is news, it will appear here.

Questions about Extrawell Pharmaceutical Holdings

What is the ticker symbol of Extrawell Pharmaceutical Holdings?

Extrawell Pharmaceutical Holdings Limited trades under the ticker 858 on HKEX.

Where is Extrawell Pharmaceutical Holdings listed?

Extrawell Pharmaceutical Holdings Limited is listed on HKEX.

Which country or territory is Extrawell Pharmaceutical Holdings listed under?

Our directory records Extrawell Pharmaceutical Holdings Limited under Hong Kong.

What does Extrawell Pharmaceutical Holdings do?

Our directory classifies Extrawell Pharmaceutical Holdings Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Extrawell Pharmaceutical Holdings?

The ISIN recorded for Extrawell Pharmaceutical Holdings Limited is BMG3285Q1134.

Does aibio.space cover Extrawell Pharmaceutical Holdings?

aibio.space lists Extrawell Pharmaceutical Holdings Limited among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Extrawell Pharmaceutical Holdings?

Companies in our directory listed in the same country and business area as Extrawell Pharmaceutical Holdings: Lee's Pharmaceutical Holdings, Pak Fah Yeow International, Beijing Tong Ren Tang Chinese Medicine Co., Sino Biopharmaceutical, Tianda Pharmaceuticals, SSY Group.

Investor discussion: Extrawell Pharmaceutical Holdings

Members talk about Extrawell Pharmaceutical Holdings (858). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Extrawell Pharmaceutical Holdings, newest first. Each line links the filing it comes from.

Oct 14, 2026Listings
Share consolidation: PROPOSED SHARE CONSOLIDATION; PROPOSED CAPITAL REDUCTION; PROPOSED SHARE SUB-DIVISION AND PROPOSED CHANGE IN BOARD LOT SIZE. Source
Sep 30, 2026Mergers
Transaction under the Listing Rules: FURTHER EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS. Source
Sep 11, 2026Mergers
Transaction under the Listing Rules: FURTHER DELAY IN DESPATCH OF CIRCULAR IN RESPECT OF THE MAJOR TRANSACTION IN RELATION TO THE PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS. Source
Jul 30, 2026Financings
Share or debt issue: PROPOSALS FOR GENERAL MANDATES TO ISSUE NEW SHARES AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING. Source
May 29, 2026Mergers
Transaction under the Listing Rules: (1) FURTHER EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS (2) FURTHER DELAY IN DESPATCH OF CIRCULAR IN RESPECT OF THE MAJOR TRANSACTION IN RELATION TO THE PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS. Source
Mar 17, 2026Mergers
Transaction under the Listing Rules: COMPLETION OF DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION OF A NON-WHOLLY OWNED SUBSIDIARY. Source
Feb 27, 2026Mergers
Transaction under the Listing Rules: (1) EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS (2) DELAY IN DESPATCH OF CIRCULAR IN RESPECT OF THE MAJOR TRANSACTION IN RELATION TO THE PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS. Source
Dec 30, 2025Mergers
Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION OF A NON-WHOLLY OWNED SUBSIDIARY. Source
Dec 2, 2025Mergers
Transaction under the Listing Rules: MAJOR TRANSACTION - PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS. Source
Sep 10, 2025Financings
Share or debt issue: COMPLETION OF ISSUE OF NEW SHARES UNDER GENERAL MANDATE AND BUSINESS UPDATE. Source
Aug 14, 2025Financings
Share or debt issue: ISSUE OF NEW SHARES UNDER GENERAL MANDATE. Source
Jul 28, 2025Financings
Share or debt issue: PROPOSALS FOR GENERAL MANDATES TO ISSUE NEW SHARES AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING. Source

Press releases

Headlines of Extrawell Pharmaceutical Holdings's own announcements, newest first. Each opens the full release on the newswire that carried it.

Oct 21, 2026HKEXnews
GRANT OF SHARE OPTIONS TO DIRECTORS AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO THE GRANT OF SHARE OPTIONS TO THE SERVICE PROVIDER
Oct 16, 2026HKEXnews
TERMINATION OF THE MEMORANDUM OF UNDERSTANDING IN RELATION TO THE POSSIBLE SALE OF THE CONVERTIBLE BONDS
Oct 14, 2026HKEXnews
PROPOSED SHARE CONSOLIDATION; PROPOSED CAPITAL REDUCTION; PROPOSED SHARE SUB-DIVISION AND PROPOSED CHANGE IN BOARD LOT SIZE
Oct 12, 2026HKEXnews
APPOINTMENT OF EXECUTIVE DIRECTOR
Sep 30, 2026HKEXnews
FURTHER EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS
Sep 11, 2026HKEXnews
FURTHER DELAY IN DESPATCH OF CIRCULAR IN RESPECT OF THE MAJOR TRANSACTION IN RELATION TO THE PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS
Aug 28, 2026HKEXnews
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 28 AUGUST 2026 AND RETIREMENT OF DIRECTOR
Jul 30, 2026HKEXnews
NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS - Notice of Publication of Annual Report 2026, Circular dated 31 July 2026 containing Notice of Annual General Meeting, and Proxy Form
Jul 30, 2026HKEXnews
NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - Notice of Publication of Annual Report 2026, Circular dated 31 July 2026 containing Notice of Annual General Meeting, and Proxy Form
Jul 30, 2026HKEXnews
NOTICE OF ANNUAL GENERAL MEETING
Jul 30, 2026HKEXnews
PROPOSALS FOR GENERAL MANDATES TO ISSUE NEW SHARES AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING
Jun 30, 2026HKEXnews
ANNUAL RESULTS FOR THE YEAR ENDED 31 MARCH 2026
Jun 23, 2026HKEXnews
PROFIT WARNING
May 29, 2026HKEXnews
(1) FURTHER EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS (2) FURTHER DELAY IN DESPATCH OF CIRCULAR IN RESPECT OF THE MAJOR TRANSACTION IN RELATION TO THE PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS
Mar 27, 2026HKEXnews
MEMORANDUM OF UNDERSTANDING IN RELATION TO THE POSSIBLE SALE OF THE CONVERTIBLE BONDS
Mar 17, 2026HKEXnews
COMPLETION OF DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION OF A NON-WHOLLY OWNED SUBSIDIARY
Feb 27, 2026HKEXnews
(1) EXTENSION OF LONG STOP DATE IN RESPECT OF PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS (2) DELAY IN DESPATCH OF CIRCULAR IN RESPECT OF THE MAJOR TRANSACTION IN RELATION TO THE PROPOSED FOURTH AMENDMENTS TO THE TERMS AND CONDITIONS OF THE BONDS
Jan 20, 2026HKEXnews
CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGES IN COMPOSITION OF BOARD COMMITTEES
Dec 30, 2025HKEXnews
DISCLOSEABLE TRANSACTION AND CONNECTED TRANSACTION AT SUBSIDIARY LEVEL IN RELATION TO A SHARE BUY-BACK TRANSACTION OF A NON-WHOLLY OWNED SUBSIDIARY
Dec 30, 2025HKEXnews
CHANGE OF CHIEF EXECUTIVE OFFICER

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:858 on TradingView.

Listing details

Company: Extrawell Pharmaceutical Holdings Limited
Ticker: 858
Listing: HKEX
Country or territory: Hong Kong
Business scope: Pharmaceuticals: Major
ISIN: BMG3285Q1134
Last quote in directory: 2026-10-22
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction